36,958 Shares in VYNE Therapeutics Inc. (NASDAQ:VYNE) Acquired by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC bought a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,958 shares of the company’s stock, valued at approximately $124,000. Bridgeway Capital Management LLC owned about 0.25% of VYNE Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of VYNE Therapeutics in the fourth quarter worth approximately $68,000. XTX Topco Ltd purchased a new position in VYNE Therapeutics in the fourth quarter valued at approximately $70,000. Adage Capital Partners GP L.L.C. purchased a new position in VYNE Therapeutics in the fourth quarter valued at approximately $516,000. Schonfeld Strategic Advisors LLC raised its holdings in VYNE Therapeutics by 4.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after buying an additional 8,058 shares during the period. Finally, Acorn Capital Advisors LLC purchased a new position in VYNE Therapeutics in the fourth quarter valued at approximately $1,531,000. 83.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright cut their price target on shares of VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating on the stock in a report on Friday, April 25th.

VYNE Therapeutics Stock Performance

NASDAQ VYNE opened at $1.31 on Wednesday. VYNE Therapeutics Inc. has a one year low of $1.18 and a one year high of $4.30. The company’s 50 day moving average price is $1.64 and its 200 day moving average price is $2.39. The firm has a market capitalization of $19.93 million, a price-to-earnings ratio of -1.52 and a beta of 1.76.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.05 million. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. Sell-side analysts forecast that VYNE Therapeutics Inc. will post -0.97 EPS for the current fiscal year.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.